Nisa Investment Advisors
BBIO icon

Nisa Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Nisa Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05M Sell
27,639
-28,592
-51% -$2.07M 0.01% 606
2025
Q4 		$4.3M Sell
56,231
-1,206
-2% -$79.2K 0.01% 447
2025
Q3 		$2.98M Buy
57,437
+30,000
+109% +$1.46M 0.01% 533
2025
Q2 		$1.18M Sell
27,437
-4,667
-15% -$170K 0.01% 760
2025
Q1 		$1.11M Buy
32,104
+193
+0.6% +$6.51K 0.01% 795
2024
Q4 		$876K Sell
31,911
-142
-0.4% -$3.67K ﹤0.01% 905
2024
Q3 		$816K Buy
32,053
+175
+0.5% +$4.59K ﹤0.01% 904
2024
Q2 		$807K Sell
31,878
-7,069
-18% -$193K 0.01% 934
2024
Q1 		$1.2M Sell
38,947
-1,273
-3% -$43.3K 0.01% 823
2023
Q4 		$1.62M Sell
40,220
-3,200
-7% -$96.1K 0.01% 717
2023
Q3 		$1.14M Sell
43,420
-7,400
-15% -$210K 0.01% 831
2023
Q2 		$874K Buy
50,820
+1,270
+3% +$19.1K 0.01% 912
2023
Q1 		$822K Buy
49,550
+1,130
+2% +$13.2K 0.01% 919
2022
Q4 		$369K Sell
48,420
-2,292
-5% -$21.9K ﹤0.01% 1201
2022
Q3 		$505K Buy
50,712
+49,831
+5,656% +$518K ﹤0.01% 1025
2022
Q2 		$8K Sell
881
-50,800
-98% -$425K ﹤0.01% 2210
2022
Q1 		$525K Sell
51,681
-330
-0.6% -$3.39K ﹤0.01% 1063
2021
Q4 		$513K Buy
52,011
+44,453
+588% +$1.88M ﹤0.01% 1006
2021
Q3 		$354 Buy
7,558
+147
+2% +$7.88K ﹤0.01% 1225
2021
Q2 		$452 Buy
7,411
+1,200
+19% +$68.5K ﹤0.01% 1162
2021
Q1 		$383 Buy
6,211
+400
+7% +$26.2K ﹤0.01% 1246
2020
Q4 		$413K Buy
5,811
+3,001
+107% +$145K ﹤0.01% 1226
2020
Q3 		$105K Buy
2,810
+2,260
+411% +$71.1K ﹤0.01% 1530
2020
Q2 		$18K Hold
550
– – ﹤0.01% 1793
2020
Q1 		$16K Buy
+550
New +$17.1K ﹤0.01% 1756

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's BBIO Position: Q1 2026 in Review

Nisa Investment Advisors reduced its BridgeBio Pharma (BBIO) stake by 51% in Q1 2026, selling an estimated $2.07M and leaving 27,639 shares worth $2.05M. The position accounts for 0.01% of the portfolio, ranked #606.

Nisa Investment Advisors first reported a position in BBIO in Q1 2020 and has held it in 25 quarters since. The position peaked at $4.3M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Nisa Investment Advisors held 27,639 shares of BridgeBio Pharma worth $2.05M as of Q1 2026.
  • Nisa Investment Advisors sold 28,592 BridgeBio Pharma shares in Q1 2026, an estimated $2.07M.
  • BridgeBio Pharma made up 0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #606 holding.
  • Nisa Investment Advisors first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 25 quarters since.
  • Nisa Investment Advisors's BridgeBio Pharma position peaked at $4.3M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.